BioSIM 抗人 TFPI 抗体 (康赛珠单抗)，生物类似

BioSIM 抗人 TFPI 抗体 (康赛珠单抗)，生物类似药，科研用途

产品基本信息

产品名称：BioSIM anti-Human TFPI Antibody (Concizumab Biosimilar), Research Grade

中文名称：BioSIM 抗人 TFPI 抗体 (康赛珠单抗)，生物类似药，科研用途

CAS号：1312299-39-0

产品货号：SIM0845-5mg

产品规格：5mg

产品类型：二抗

供应商：InvivoCrown

产品背景

康赛珠单抗是一种靶向组织因子途径抑制剂(TFPI)的人源化单克隆抗体，作为血友病治疗领域的重要研究工具。本产品为康赛珠单抗的生物类似药，专为科研用途设计。该重组生物类似抗体在严格的无动物成分设施中生产，采用先进的体外无蛋白细胞培养技术，确保产品批次间的高度一致性。

生产过程中采用多步骤纯化工艺，其中包括Protein A或G的色谱纯化步骤，有效去除杂质，保证产品纯度。这种严谨的生产工艺使该抗体适合用于多种体外和体内研究应用。

产品特点

• 高纯度：经过多步纯化工艺，包括Protein A或G色谱纯化
• 无动物成分生产：在无动物成分的设施中生产，降低外源因子污染风险
• 人源化设计：人源化抗体结构，更适合人类相关研究
• 批次一致性：标准化生产工艺确保不同批次间的一致性

应用领域

本产品适用于多种科研应用场景，包括但不限于：

• ELISA：可用于检测和定量人TFPI蛋白
• FACS：适用于细胞表面TFPI蛋白的流式细胞术分析
• 功能性实验：可用于研究TFPI在凝血通路中的功能调节作用
• 体内研究：适用于动物模型中的体内药效学研究

靶点信息

免疫原：具体免疫原信息请参考产品说明书

反应性：Human

来源宿主：Humanized

储存条件

为确保产品活性和稳定性，请遵循以下储存建议：

• 短期储存：如1-2周内使用，建议在4°C条件下保存
• 中期储存：如12个月内使用，建议在-20°C条件下保存
• 长期储存：超过12个月的储存需求，建议在-80°C条件下保存
• 重要提示：为避免产品活性降低，请避免反复冻融。建议分装后储存

研究领域

本产品主要应用于血友病相关研究，特别适合于凝血机制、TFPI功能研究以及新型血友病治疗方法开发等科研方向。作为研究工具，该抗体可帮助科研人员深入理解TFPI在凝血过程中的作用机制，为血友病治疗策略的开发提供重要支持。

注意：以上信息可能随着产品优化升级等因素产生变动，具体信息请咨询亚科因公司。

BioSIM anti-Human TFPI Antibody (Concizumab Biosimilar), Research Grade

Product Basic Information

Product Name: BioSIM anti-Human TFPI Antibody (Concizumab Biosimilar), Research Grade

Chinese Name: BioSIM 抗人 TFPI 抗体 (康赛珠单抗)，生物类似药，科研用途

CAS Number: 1312299-39-0

Product Catalog Number: SIM0845-5mg

Product Specification: 5mg

Product Type: Secondary Antibody

Supplier: InvivoCrown

Product Background

Concizumab is a humanized monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), serving as an important research tool in the field of hemophilia treatment. This product is a biosimilar of Concizumab, specifically designed for research purposes. This recombinant biosimilar antibody is produced in strict animal-free facilities using advanced animal-free in vitro cell culture technology, ensuring high consistency between product batches.

The production process involves a multi-step purification process, including Protein A or G chromatography steps, which effectively removes impurities and ensures product purity. This rigorous production process makes the antibody suitable for various in vitro and in vivo research applications.

Product Features

• High Purity: Purified through multi-step process, including Protein A or G chromatography
• Animal-Free Production: Produced in animal-free facilities, reducing the risk of exogenous factor contamination
• Humanized Design: Humanized antibody structure, more suitable for human-related research
• Batch Consistency: Standardized production process ensures consistency between different batches

Application Fields

This product is suitable for various research applications, including but not limited to:

• ELISA: Can be used for detection and quantification of human TFPI protein
• FACS: Suitable for flow cytometry analysis of cell surface TFPI protein
• Functional Assays: Can be used to study the functional regulatory role of TFPI in coagulation pathways
• In Vivo Studies: Suitable for pharmacodynamic studies in animal models

Target Information

Immunogen: For specific immunogen information, please refer to the product manual

Reactivity: Human

Host Source: Humanized

Storage Conditions

To ensure product activity and stability, please follow the storage recommendations below:

• Short-term Storage: If to be used within 1-2 weeks, storage at 4°C is recommended
• Medium-term Storage: If to be used within 12 months, storage at -20°C is recommended
• Long-term Storage: For storage periods exceeding 12 months, storage at -80°C is recommended
• Important Note: To avoid product activity reduction, avoid repeated freeze-thaw cycles. Aliquot storage is recommended

Research Areas

This product is mainly applied to hemophilia related research, particularly suitable for research directions such as coagulation mechanisms, TFPI function studies, and development of novel hemophilia treatments. As a research tool, this antibody can help researchers gain an in-depth understanding of the mechanism of action of TFPI in the coagulation process, providing important support for the development of hemophilia treatment strategies.

Note: The above information may change due to factors such as product optimization and upgrades. For specific information, please consult Yacoin Company.